KalVista Pharmaceuticals (KALV) Free Cash Flow Growth (1y) (2015 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 60.84% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 88.70% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.72% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 66.37% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 3.98% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 137.65% |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | -35.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -35.66% |
| Apr 30, 2025 | -174.06% |
| Oct 31, 2024 | -100.27% |
| Jul 31, 2024 | -50.67% |
| Apr 30, 2024 | 34.58% |
| Jan 31, 2024 | -199.41% |
| Oct 31, 2023 | 4.61% |
| Jul 31, 2023 | -12.99% |
| Apr 30, 2023 | 15.52% |
| Jan 31, 2023 | 34.79% |
| Oct 31, 2022 | -4.45% |
| Jul 31, 2022 | -31.30% |
| Apr 30, 2022 | -142.60% |
| Jan 31, 2022 | -87.72% |
| Oct 31, 2021 | -149.86% |
| Jul 31, 2021 | -399.22% |
| Apr 30, 2021 | 12.26% |
| Jan 31, 2021 | 42.02% |
| Oct 31, 2020 | -0.47% |
| Jul 31, 2020 | 68.26% |
| Apr 30, 2020 | -17.06% |
| Jan 31, 2020 | -20.53% |
| Oct 31, 2019 | 11.98% |
| Jul 31, 2019 | -67.82% |
| Apr 30, 2019 | -53.23% |
| Jan 31, 2019 | -138.79% |
| Oct 31, 2018 | -23.21% |
| Jul 31, 2018 | -48.68% |
| Apr 30, 2018 | -165.82% |
| Jan 31, 2018 | 349.29% |
| Oct 31, 2017 | -73.88% |
| Jul 31, 2017 | 19.99% |
| Mar 31, 2016 | -24.57% |
| Sep 30, 2015 | -64.87% |
| Jun 30, 2015 | -223.89% |
| Mar 31, 2015 | -140.97% |